MDG_LOGO_2016_GRAY_RGB.jpg
Medigene Presents Progress on KRAS Library and UniTope & TraCR Technology at ESMO 2024
September 14, 2024 07:30 ET | Medigene AG
Planegg/Martinsried, September 14, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Logo.png
UPDATE - IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
September 09, 2024 16:06 ET | Imunon, Inc.
September 18th Event in New York City to Include a Review of the Opportunity for Investigational Therapy IMNN-001 (IL-12) to Treat Advanced Ovarian Cancer and Clinical Development Timeline ...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene Announces U.S. FDA Clearance of IND Application for MDG1015, a First-in-Class, Third Generation T Cell Receptor Engineered T Cell (TCR-T) Therapy for Multiple Solid Tumor Indications
September 05, 2024 08:00 ET | Medigene AG
Planegg/Martinsried, September 5, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
EpimAb_Logo_For Notified.png
EpimAb Biotherapeutics and Vignette Bio Announce Strategic Collaboration to Develop EMB-06, a BCMA×CD3 Bispecific Antibody
September 03, 2024 21:00 ET | Shanghai EpimAb Biotherapeutics Co., Ltd.
SHANGHAI and SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, Inc. (“EpimAb” or “EpimAb Biotherapeutics”) a clinical stage biopharmaceutical company specializing in the...
Alumis.png
Alumis to Participate in Upcoming September Investor Conferences
September 03, 2024 16:29 ET | Alumis Inc.
Alumis will be participating in several investor conferences in September
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene AG Secures Two Additional Patents for Technologies in Its End-to-End Platform
August 29, 2024 05:00 ET | Medigene AG
Planegg/Martinsried, August 29, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Immunology Market to Reach $204.0 Billion, Globally, by 2033 at 6.3% CAGR: Allied Market Research
August 28, 2024 06:40 ET | Allied Analytics LLP
Wilmington, Delaware, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, "Immunology Market by Product Type (Diagnostic Testing Equipment, Biomarkers and...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene to Present at Upcoming Investor Conferences
August 28, 2024 05:00 ET | Medigene AG
Planegg/Martinsried, August 28, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
SNS-INSIDER-300X300.jpg
Immunology Market Size to Hit USD 254.23 Billion by 2032, Driven by Rising Prevalence of Autoimmune Diseases & Advances in Biologic Therapies | SNS Insider
August 22, 2024 09:00 ET | SNS Insider pvt ltd
Pune, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Immunology Market Analysis: “The Immunology Market Size was valued at USD 97.58 Billion in 2023 and is expected to reach USD 254.23 Billion by 2032 and...
GeoVax.png
GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board
August 08, 2024 09:00 ET | GeoVax, Inc.
Strategic Appointment Enhances GeoVax’s Leadership and Expertise in Vaccine Development ATLANTA, GA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...